Ran Jun-Tao, Zhou Yong-Ning, Tang Cheng-Wei, Li Hong-Hua, Li Xing-Wen, Lu Hong
Department of Gastroenterology, The First Hospital Affiliated Lanzhou University, Lanzhou, Gansu, 730000, PR China.
Ai Zheng. 2009 Apr;28(4):361-5.
Cyclooxygenase-2 (COX-2) inhibitors have been shown to exert chemopreventive effects against gastrointestinal carcinomas. This study was to investigate the effect of celecoxib, a selective COX-2 inhibitor, on the expression of E-cadherin and serum levels of soluble E-cadherin in gastric carcinomas.
Fifty-nine gastric carcinoma patients were randomly divided into two groups: surgery group (n=22) and celecoxib plus surgery group (n=37). Patients in the surgery group underwent surgical resection after diagnosis, while patients in the celecoxib plus surgery group received oral celecoxib, 200 mg twice daily for six days before curative resection. Twenty healthy subjects were recruited as normal controls. COX-2 and E-cadherin expressions were detected by immunohistochemistry. Serum levels of soluble E-cadherin were quantitatively measured using a commercially available enzyme-linked immunosorbent assay (ELISA) kit.
Compared to the surgery group, the expression of COX-2 was significantly lower while that of E-cadherin was significantly higher in celecoxib plus surgery group. The concentrations of serum soluble E-cadherin before treatment were significantly higher in the surgery [(53.47+/-9.62) ng/mL] and the celecoxib plus surgery [(51.57+/-9.79) ng/mL] groups than in the control group [(37.17+/-5.38) ng/ml] (P<0.01). The soluble E-cadherin levels after surgery in both groups [(39.29+/-7.72) ng/mL and (29.29+/-8.28) ng/mL] were significantly lower than those before surgery (P<0.01). The soluble E-cadherin level on the sixth day [(44.11+/-8.36) ng/mL] was significantly lower than that before treatment in the celecoxib plus surgery group (P<0.01).
Short-term preoperative treatment of celecoxib up-regulates the expression of E-cadherin in gastric carcinomas.
环氧合酶-2（COX-2）抑制剂已被证明对胃肠道癌具有化学预防作用。本研究旨在探讨选择性COX-2抑制剂塞来昔布对胃癌中E-钙黏蛋白表达及血清可溶性E-钙黏蛋白水平的影响。
59例胃癌患者随机分为两组：手术组（n = 22）和塞来昔布联合手术组（n = 37）。手术组患者确诊后接受手术切除，而塞来昔布联合手术组患者在根治性切除术前6天口服塞来昔布，每日2次，每次200 mg。招募20名健康受试者作为正常对照。采用免疫组织化学法检测COX-2和E-钙黏蛋白的表达。使用市售酶联免疫吸附测定（ELISA）试剂盒定量检测血清可溶性E-钙黏蛋白水平。
与手术组相比，塞来昔布联合手术组中COX-2的表达显著降低，而E-钙黏蛋白的表达显著升高。手术组[（53.47±9.62）ng/mL]和塞来昔布联合手术组[（51.57±9.79）ng/mL]治疗前血清可溶性E-钙黏蛋白浓度显著高于对照组[（37.17±5.38）ng/ml]（P < 0.01）。两组术后可溶性E-钙黏蛋白水平[（39.29±7.72）ng/mL和（29.29±8.28）ng/mL]均显著低于术前（P < 0.01）。塞来昔布联合手术组第6天可溶性E-钙黏蛋白水平[（44.11±8.36）ng/mL]显著低于治疗前（P < 0.01）。
术前短期使用塞来昔布可上调胃癌中E-钙黏蛋白的表达。
